Adults aged ≥18 years with a risk condition are recommended to receive pneumococcal vaccine

A single dose of 21vPCV is recommended for people aged ≥18 years with a risk condition see Table. Risk conditions for pneumococcal vaccination and eligibility for NIP funding.

People who have previously received a dose of any pneumococcal vaccine (including 23vPPV [a pneumococcal polysaccharide vaccine], 13vPCV, 15vPCV, or 20vPCV) are recommended to receive this dose of 21vPCV at least 12 months after their last dose.

Children diagnosed with a risk condition before 18 years of age who received a dose of 20vPCV are recommended to receive a dose of 21vPCV at 18 years of age. See Infographic. Pneumococcal vaccination for people who have previously received a pneumococcal vaccine.

Adults aged ≥65 years and Aboriginal and Torres Strait Islander adults aged ≥25 years who develop a risk condition and have already received a 21vPCV as part of the adult program do not need another dose of 21vPCV. 

People who have received a haematopoietic stem cell transplant are recommended to receive 3 doses of 21vPCV regardless of previous pneumococcal vaccine history. See Table. Recommendations for vaccination after haematopoietic stem cell transplant in children and adults.

21vPCV is funded through the NIP for people aged ≥18 years with certain risk conditions. See Table. Risk conditions for pneumococcal vaccination and eligibility for NIP funding For details see the National Immunisation Program Schedule.